NeuroMetrix (NASDAQ:NURO) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report sent to investors on Tuesday morning. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Up 0.7 %

NeuroMetrix stock opened at $4.05 on Tuesday. NeuroMetrix has a twelve month low of $2.66 and a twelve month high of $6.00. The company has a market capitalization of $8.14 million, a P/E ratio of -0.64 and a beta of 2.28. The stock’s 50 day moving average is $3.61 and its 200 day moving average is $3.84.

NeuroMetrix (NASDAQ:NURO) last released its earnings results on Tuesday, August 6th. The medical device company reported ($0.74) EPS for the quarter. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%. The company had revenue of $0.77 million during the quarter.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.